Research
Immunogenicity risk assessment of novel modalities using new approach methodologies
Nature · By Vijaya L. Simhadri ·
The Brief
- Published online in Nature Reviews Drug Discovery on 13 November 2026.
- Covers immunogenicity risk assessment of novel therapeutic modalities such as cell therapies and gene editors.
- Notes that unwanted immune responses limit the clinical progression of these modalities.
Why it matters
Unwanted immune responses can slow or block the clinical development of promising cell therapies and gene editors, so better methods for assessing that risk matter to drug developers and clinical researchers.
Who’s affected
- drug developers working on cell therapies and gene editors
- researchers assessing immunogenicity in clinical development
- #immunogenicity
- #cell therapy
- #gene editing
- #drug development
- #risk assessment
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/s41573-026-01562-9 Novel therapeutic modalities such as cell therapies and gene editors could potentially treat many diseases, but their clinical progression is limited by unwanted immune responses…
Timeline
Published online in Nature Reviews Drug Discovery
nature.com
Immunogenicity risk assessment of novel modalities using new approach methodologies